Explore this article's sources with AI
Follow PeptideMethods on Google
Tirzepatide and Retinopathy in Type 1
A chart review found similar proportions of new diabetic retinopathy with off-label tirzepatide and matched controls in type 1 diabetes.
Why we wrote this. The headline invites a causal reading. The study supports a narrower comparison with important ascertainment limits.
In this article (6 sections)
A retrospective chart review found new diabetic retinopathy in 10 of 39 adults with type 1 diabetes who used adjunctive tirzepatide and had no recorded eye disease at baseline. That proportion, 25.6%, was close to the 29.2% recorded among 24 matched controls who did not use tirzepatide. The study does not show that tirzepatide caused or prevented retinal disease[1].
What the study measured
Polsky and colleagues reviewed records for 106 adults with type 1 diabetes and overweight or obesity who used tirzepatide continuously for at least one year, allowing a two-month window around that duration. Temporary interruptions of one month or less were permitted. They compared those records with 85 controls matched by age and sex, with body mass index also included in the matching. Mean diabetes duration was 26.2 years in cases and 28.0 years in controls. This was an observational comparison based on clinical care, not a randomized trial[1].
The researchers collected retinal examination findings at baseline and again 6 to 24 months later. They assessed new diabetic retinopathy and diabetic macular edema among people without either condition at baseline. For people who already had retinal disease, they assessed whether it changed or remained stable. The accessible PubMed record does not describe a central reading center, masked image grading, one required imaging method, or identical visit timing across groups[1].
The retinal findings
Retinal disease was common before follow-up began. At baseline, 63.2% of tirzepatide cases and 71.8% of controls had diabetic retinopathy, diabetic macular edema, or both. Among the smaller subgroup without baseline eye disease, new retinopathy appeared in 10 of 39 cases and 7 of 24 controls. Mean follow-up differed between those groups: 11.7 months for cases and 15.3 months for controls. The raw percentages therefore should not be read as equal observation rates over equal periods[1].
Most participants who already had diabetic retinopathy remained stable at follow-up, according to the abstract. The record does not provide the full severity distribution, eye-level counts, complete progression and regression estimates, or diabetic macular edema results needed for a more detailed comparison. Those omissions matter because a stable mild lesion and a stable vision-threatening lesion are not interchangeable outcomes[1].
The HbA1c signal needs care
Mean glycated hemoglobin, or HbA1c, improved within six months in the tirzepatide group and then remained stable. It did not change in controls. Across both groups, incident retinopathy was more frequent among participants whose HbA1c fell by at least 0.5 percentage points within six months: 11 of 28, or 39.3%, compared with 6 of 35, or 17.1%, among those without that decline. The reported P value was 0.048[1].
That pooled association cannot separate the effect of glucose change from treatment choice, diabetes history, baseline retinal risk, or other differences recorded imperfectly in routine care. It also does not establish a safe rate of HbA1c change. The current US Mounjaro label states that temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control and advises monitoring people with a history of diabetic retinopathy for progression[2].
Adjunctive and off-label in type 1 diabetes
The paper describes tirzepatide as adjunctive treatment, meaning it was added to type 1 diabetes care rather than replacing insulin. Most participants in both groups used an automated insulin delivery system. The authors explicitly call this use off-label. The current US Mounjaro prescribing information lists indications for type 2 diabetes, not type 1 diabetes[1][2].
Nothing in this chart review supports starting, stopping, or changing tirzepatide or insulin without clinical supervision. Readers looking for the drug's approved uses and broader safety record can review our tirzepatide evidence page and the country regulation overview. The study addresses retinal observations in one selected clinical cohort, not the overall benefit-risk balance of adjunctive treatment in type 1 diabetes.
What this study cannot establish
Retrospective matching can reduce some visible differences, but it does not create random treatment assignment. The abstract reports matching on age, sex, and body mass index. It does not show that groups were matched on baseline HbA1c, retinal severity, diabetes duration, blood pressure, kidney disease, or access to eye care. Treatment selection and unmeasured clinical differences could influence the result[1].
The incident-retinopathy analysis involved only 63 people, split into 39 cases and 24 controls. Follow-up ranged from 6 to 24 months, and mean follow-up was not the same between groups. The accessible record also does not report a time-to-event model or adjusted effect estimate for the main comparison. The percentages are useful descriptive data, but they are not a precise estimate of comparative risk[1].
Why randomized evidence is still needed
The authors concluded that adults with type 1 diabetes and overweight or obesity who received off-label tirzepatide developed diabetic retinopathy at a proportion similar to controls. They also called for randomized controlled trials. A useful trial would standardize retinal imaging and grading, align examination times, stratify participants by baseline retinal disease, and prespecify how glycemic change is analyzed. Longer follow-up would be needed to assess sustained progression and vision-threatening outcomes[1].
Frequently asked
Did tirzepatide cause diabetic retinopathy in this study?
The study cannot answer that. It was a retrospective chart review, not a randomized trial. New retinopathy was recorded in 25.6% of tirzepatide cases and 29.2% of controls without baseline eye disease, with different mean follow-up times.
Is tirzepatide approved for type 1 diabetes?
No. The paper describes tirzepatide use in this cohort as off-label and adjunctive to type 1 diabetes care. The current US Mounjaro label lists indications for type 2 diabetes, not type 1 diabetes.
Why did the researchers examine HbA1c change?
Rapid improvement in glucose control has been associated with temporary worsening of diabetic retinopathy. In this study, incident retinopathy was more frequent across both groups when HbA1c fell by at least 0.5 percentage points within six months, but the observational result does not prove causation.
Sources
No revisions yet. First published .